Retatrutide in Philadelphia, PA: status & local weight-loss providers

No. Retatrutide is investigational and not FDA-approved, so it is not available by prescription in Philadelphia or anywhere else in the U.S. The only legitimate routes today are clinical trials and Lilly's expanded access program, where your physician applies on your behalf and medical criteria must be met. RetaMaps tracks the status and the local providers most relevant to future treatment.

They are practices in medical weight management, obesity medicine, endocrinology, metabolic health, and related fields. Some currently advertise FDA-approved GLP-1 medications such as semaglutide or tirzepatide; each profile shows what the practice publicly advertises today.

Yes — 28 of the 39 tracked providers in this market indicate telehealth visits. State licensing rules determine whether a given telehealth practice can serve Pennsylvania residents; confirm with the practice.

No. Inclusion on RetaMaps does not mean a provider offers or will offer retatrutide — and no legitimate provider can prescribe it today. Where a practice has told RetaMaps directly that it expects to offer retatrutide if approved, we mark that clearly on its profile.

Join the RetaMaps update list with your email and ZIP. We'll email when retatrutide's regulatory or commercial status changes relevant to your area. It's informational — not a treatment queue.